EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)

Impact of a High‐Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor

Panli Cardona, Sandeep Dutta, Brett Houk

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1452 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Panli Cardona und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, CA, USA. Hauptthemen laut MEDLINE: Food-Drug Interactions, Proto-Oncogene Proteins p21(ras), Area Under Curve. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sotorasib is a small molecule drug that specifically and irreversibly inhibits the KRAS p.G12C mutant protein. This analysis investigated the impact of a high‐calorie high‐fat meal on the pharmacokinetics, safety, and tolerability of sotorasib in both healthy volunteers and patients with KRAS G12C advanced solid tumors. Each subject received a single oral dose of 360 or 960 mg of sotorasib under fasted conditions or with a high‐fat meal (fed conditions). The geometric least squares means (GLSM) ratios (fed/fasted) for 360 mg of sotorasib C max and AUC inf were 1.03 and 1.38, respectively, in healthy volunteers (N = 14). The GLSM ratios (fed/fasted) for C max and AUC 0‐24h were 1.38 and 1.75, respectively, with 360 mg of sotorasib in cancer patients (N = 2). The GLSM ratios (fed/fasted) for C max and AUC 0‐24h were 0.660 and 1.25, respectively, with 960 mg of sotorasib in cancer patients (N = 8). Sotorasib was well tolerated in fast and fed conditions. The impact of a high‐fat meal on sotorasib exposure is less than a 2‐fold increase or decrease in C max and AUCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Food-Drug InteractionsProto-Oncogene Proteins p21(ras)Area Under CurveHumansMaleFemaleMiddle AgedAdultAgedDiet, High-FatNeoplasmsYoung AdultCross-Over StudiesPyrimidinesAdministration, OralPyridinesAntineoplastic AgentsHealthy VolunteersDietary FatsFastingPiperazines

Stichwörter der Autor:innen

KRAS inhibitorsbiopharmaceuticsfood effectfood‐drug interactionpharmacokineticssotorasib

Substanzen

Proto-Oncogene Proteins p21(ras)sotorasibKRAS protein, humanPyrimidinesPyridinesAntineoplastic AgentsDietary FatsPiperazines

Autor:innen und Institutionen

  • Clinical Pharmacology, Modeling and Simulation, Amgen Inc., Thousand Oaks, CA, USA.

Zitieren

APA

Cardona, P., Dutta, S., & Houk, B. (2024). Impact of a High‐Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1452

Vancouver

Cardona P, Dutta S, Houk B. Impact of a High‐Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1452

BibTeX
@article{Cardona2024,
  author = {Cardona, Panli and Dutta, Sandeep and Houk, Brett},
  title = {Impact of a High‐Fat Meal on the Pharmacokinetics of Sotorasib, a KRAS G12C Inhibitor},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1452}
}
Kostenlos starten →